Sanofi (SNY)

The company now

Sanofi reported third-quarter 2026 net sales of €14,444 million on 30 October, up 14.3 percent at constant exchange rates, and raised its 2026 guidance 1.

The company now expects 2026 sales to grow by a low-teens percentage and business earnings per share, its adjusted profit measure, by a mid-teens percentage, both at constant rates 1. Business earnings per share was €3.55 in the quarter, up 19.6 percent 1.

Dupixent, the antibody for eczema, asthma and related diseases that Sanofi shares with Regeneron, brought in €5,687 million, up 34.8 percent 1. Vaccines sales fell 6.6 percent to €3,185 million, which the company tied to the timing of flu deliveries and lower Beyfortus sales in the US 1.

On 1 October Sanofi agreed to pay Regeneron $1 billion upfront, with up to $7 billion more in milestones, to add four long-acting antibodies to their alliance 3. Chief executive Belén Garijo said the priority is to protect earnings through Dupixent's loss of exclusivity 1.

The open question is how the company replaces Dupixent's sales after its main US patent protection ends in March 2031, a point the annual report sets out 2. The next results are due on 28 January 2027 1.

As of Nov 4, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.